[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-ductal-adenocarcinoma-pdac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-ductal-adenocarcinoma-pdac":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,50,63,92,119,152,184,205,240,279,312,332,367,389,413,438,462,490,514,538,568,597,616,643,669],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100054140","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pancreatic-cancer-100054140",false,"NCT07644559","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)","Inclusion Criteria:\n\n* Histopathology confirmed PDAC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\nAdequate organ function\n\nVS-7375 + cetuximab (2L PDAC) :\n\n-Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months\n\nVS-7375 + cetuximab (1L PDAC) :\n\n-Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease\n\nExclusion criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer",[27,28],"Pancreatic Ductal Adenocarcinoma (PDAC)","G12D Mutated KRAS",[30,31,32,33,34,35,36],"KRAS G12D mutation","KRAS","PDAC","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer","Pancreatic Neoplasms","RAS","RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2026-06-16",{"date":45,"type":21},"2028-12",{"name":47,"class":48},"Verastem, Inc.","INDUSTRY",15,{"id":51,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":25,"conditions":54,"keywords":55,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":62},"100641650",{"count":20,"type":21},[24],[27,28],[30,31,32,33,34,35,36],"2026-07-01",{"date":58,"type":41},"2026-07-02",{"date":43,"type":41},{"date":45,"type":21},{"name":47,"class":48},14,{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100627609","phase-2-a-study-of-nuzefatide-pevedotin-bt5528-in-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-pdac-100627609","NCT07450859","A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","Inclusion Criteria\n\n* At least 18 years of age at the time of signature of the informed consent form\n* Measurable disease as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy of at least 12 weeks\n* Histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC)\n* Participants must have failed only 1 prior line of therapy with evidence of radiographic progression. Neoadjuvant or adjuvant systemic therapy may count as the first line if the participant progressed less than 6 months from the end of systemic therapy. Prior treatment with KRAS inhibitors is permitted\n* Participants must have sufficient tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers\n* Adequate organ function (hematologic, renal, and hepatic)\n* Negative pregnancy test for participants of childbearing potential (POCBP)\n* Must be willing and able to comply with the protocol and study procedures\n\nExclusion Criteria\n\n* Chemotherapy or radiotherapy within 14 days prior to the first dose of study treatment\n* Experimental treatments within 28 days or 5 half-lives, whichever is longer, of first dose of nuzefatide study treatment\n* Prior treatment with taxane therapy (e.g., paclitaxel) for pancreatic cancer or prior treatment with any MMAE-containing agent\n* Known microsatellite instability-high (MSI-H) status and are eligible for immune checkpoint inhibitor therapy\n* Prior toxicities must have resolved to Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0\n* Untreated central nervous system (CNS) metastases\n\nNote: Additional protocol defined Inclusion\u002FExclusion criteria apply",{"count":71,"type":21},39,[24],"This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment.\n\nThe drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2.\n\nThe main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.",[27],[34,76,77,78,79,80,33,32,81],"BT5528","EphA2","Bicycle Drug Conjugate","MMAE","Metastatic","Nuzefatide Pevedotin","2026-06-26",{"date":84,"type":41},"2026-06-30",{"date":86,"type":41},"2026-03-05",{"date":88,"type":21},"2029-05",{"name":90,"class":48},"BicycleTx Limited",3,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":49},"100609679","phase-3-using-18f-fapi-pet-to-detect-metastatic-disease-in-patients-that-have-pancreatic-ductal-adenocarcinoma-pdac-100609679","NCT07217717","Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)","A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET\u002FCT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma","FAPI-PRO","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years.\n* Participants with confirmed PDAC, undergoing staging evaluation for treatment planning.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2:\n* Provided signed, written informed consent obtained prior to any study-related procedures.\n* Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \\[¹⁸F\\]FAPI-74 administration.\n* For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner , during the trial intervention period.\n\nExclusion Criteria:\n\n* Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.\n* Known hypersensitivity to \\[¹⁸F\\]FAPI-74.\n* Administration of another investigational therapeutic or diagnostic product within 30 days prior to \\[¹⁸F\\]FAPI-74 administration.\n* Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \\[¹⁸F\\]FAPI-74 administration.\n* Previous cancer diagnosis (except basal cell carcinoma of the skin or in situ carcinoma of the cervix\u002Futerus). Participants treated with curative intent and disease-free for more than 5 years are permitted.\n* Hepatic function: T. bili \\>1.5X ULN or alk phos, ALT, or AST \\>5X ULN\n* Renal function: GFR \\\u003C 30 mL\u002Fmin\n* Pregnant or breast feeding (a negative pregnancy test is required in women of childbearing potential)\n* Inability to undergo the PET\u002FCT scanning procedure.\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis)\n* Sarcoidosis\n* Treatment, including chemotherapy, radiation or surgery for curative intent of PDAC.",{"count":101,"type":21},200,[103],"PHASE3","This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET\u002FCT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET\u002FCT screening. SOC procedures and interventions will be captured during 3 months +\u002F-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET\u002FCT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \\[¹⁸F\\]FAPI-74 PET\u002FCT.",[27],[32,107,108,109,110,111],"FAP","FAPI","PET","Fibroblast Activation Protein","Fibroblast Activation Protein Inhibitor",{"date":84,"type":41},{"date":114,"type":41},"2025-12-11",{"date":116,"type":21},"2027-12-31",{"name":118,"class":48},"SOFIE",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":137,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100630728","phase-3-study-of-daraxonrasib-and-daraxonrasib--gnp-as-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100630728","NCT07491445","Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.\n* Documented RAS mutation status, either mutant or wild-type.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":128,"type":21},900,[103],"The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.",[34,132,32,133,27,134,135,136],"Pancreatic Cancer Metastatic","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma",[34,32,33,36,31,138,139,140,141,132,134,136,135],"NRAS","HRAS","RAS Wild-Type","RAS Mutation","2026-06-24",{"date":144,"type":41},"2026-06-25",{"date":146,"type":41},"2026-03-09",{"date":148,"type":21},"2029-03",{"name":150,"class":48},"Revolution Medicines, Inc.",13,{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100636166","phase-3-atebimetinib--gnp-as-a-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100636166","NCT07562152","Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","MAPKeeper 301","Inclusion Criteria:\n\n* Must be ≥18 years of age\n* Must have confirmed diagnosis according to AJCC staging as follows:\n\n  * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must be treatment naive as follows:\n\n  * First-line PDAC participants will have received no previous systemic anti-cancer therapy\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma\n* Participants with only locally advanced disease\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases",{"count":161,"type":21},510,[103],"The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.",[34,132,32,133,33,134,27,135],[166,167,168,169,170,171,172,173],"mitogen-activated protein kinase (MAPK)","MAPK","MEK","metastatic cancer","gemcitabine","nab-paclitaxel","nab-p","atebimetinib","2026-06-18",{"date":176,"type":41},"2026-06-22",{"date":178,"type":21},"2026-06",{"date":180,"type":21},"2029-02",{"name":182,"class":48},"Immuneering Corporation",19,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":91},"100641682","phase-3-study-of-zoldonrasib--chemo-of-investigators-choice-vs-placebo--chemo-of-investigators-choice-as-first-line-treatment-in-metastatic-kras-g12d-mutated-pancreatic-adenocarcinoma--rasolute-305--100641682","NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )","RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma","RASolute 305","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to screening.\n* Documented KRAS G12D mutation status.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.\n* Prior systemic RAS-targeted therapy any time prior to randomization.\n* Presence of other known driver mutations with approved targeted therapies\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":193,"type":21},670,[103],"The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.",[34,132,32,133,27,134,135,136],[34,32,33,36,31,141,132,134,136,135],"2026-06-12",{"date":43,"type":41},{"date":201,"type":41},"2026-05-22",{"date":203,"type":21},"2030-04-22",{"name":150,"class":48},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":239},"100643204","ctdna-monitoring-after-pancreatic-cancer-surgery-k-4care-lite-study-100643204","NCT07597252","ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)","A Prospective Observational Study of Circulating Tumor DNA Dynamic Monitoring Using K-4CARE Lite Platform After Curative Resection of Pancreatic Cancer","K4CARE-PDAC","Inclusion Criteria:\n\n* Age 20 years or older\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), including its histological subtypes\n* Has undergone curative-intent resection (R0 or R1, defined as margin \\\u003C1 mm), via pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy\n* Post-operative pathologic stage at least pT1, with N0 or N1 or higher\n* Computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks before enrollment confirming no evidence of residual tumor and no distant metastasis\n* Intent to receive adjuvant chemotherapy\n* Sufficient surgical FFPE tumor tissue available for genomic sequencing\n* Able to understand and provide signed informed consent\n* Patients with or without prior neoadjuvant chemotherapy are both eligible\n\nExclusion Criteria:\n\n* Post-operative pathologic stage IV (distant metastasis), or R2 resection\n* Concurrent active primary malignancy (except cured non-melanoma skin cancer or carcinoma in situ within the past 5 years)\n* Severe post-operative complications precluding initiation of adjuvant chemotherapy within 12 weeks\n* Receipt of post-operative radiation therapy\n* Known hematologic disease or myeloproliferative disorder that may significantly affect ctDNA assay accuracy\n* Pregnant or breastfeeding women\n* Unable to comply with the protocol-specified blood draw schedule","20 Years",{"count":215,"type":21},30,"OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years. Current post-operative surveillance relies on computed tomography (CT) imaging and the serum tumor marker CA 19-9, but both have limited sensitivity for detecting microscopic residual disease.\n\nThis single-center, prospective observational study evaluates the use of the K-4CARE Lite platform-a tumor-informed plus tumor-agnostic circulating tumor DNA (ctDNA) assay with a limit of detection of 0.005%-for dynamic monitoring of minimal residual disease (MRD) in patients with resected PDAC.\n\nThirty adult patients who have undergone R0 or R1 (margin \\\u003C1 mm) resection at Linkou Chang Gung Memorial Hospital will be enrolled over 24 months. Each participant will provide one baseline tumor tissue sample (formalin-fixed paraffin-embedded) and three serial blood samples at three pre-specified study timepoints: Timepoint 1 (Week 4 to Week 10 after surgery, before adjuvant chemotherapy); Timepoint 2 (12 weeks after Timepoint 1, approximately 3 months into adjuvant chemotherapy); and Timepoint 3 (at completion of adjuvant chemotherapy, approximately Month 6 after surgery). A fourth long-term follow-up phase (Timepoint 4) collects results from patient-funded ctDNA testing performed as part of routine care.\n\nThe primary outcome is the cumulative MRD detection rate across the three pre-specified post-surgical timepoints (Timepoint 1, Timepoint 2, and Timepoint 3). Secondary outcomes include the association between ctDNA status and disease-free survival (DFS) and overall survival (OS), molecular clearance rate at Timepoint 3, lead time of molecular relapse over imaging, and platform performance. ctDNA results are reported back to the treating physician for reference but do not mandate treatment changes-all clinical decisions remain at the physician's discretion per standard guidelines.\n\nThis study aims to generate the prospective evidence base needed to design future ctDNA-guided interventional trials in pancreatic cancer.",[27,219],"NGS Monitor MRD",[221,222,223,224,225,226,227],"pancreatic cancer","circulating tumor DNA","minimal residual disease","tumor-informed sequencing","adjuvant chemotherapy","liquid biopsy","K-4CARE Lite","NOT_YET_RECRUITING","2026-06-07",{"date":231,"type":41},"2026-06-10",{"date":233,"type":21},"2026-06-01",{"date":235,"type":21},"2029-04-30",{"name":237,"class":238},"Chang Gung Memorial Hospital","OTHER",1,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":252,"conditions":253,"keywords":260,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100518120","phase-1-ko-2806-monotherapy-and-combination-therapies-in-advanced-solid-tumors-100518120","NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors","FIT-001","Inclusion Criteria:\n\n* At least 18 years of age.\n* Histologically or cytologically confirmed advanced solid tumors\n\n  * Arm #1 (KO-2806 monotherapy): Patients who have progressed on, or are refractory to, standard of care (SOC) treatments with advanced solid tumors, specifically: HRAS-mutant and\u002For amplified tumors (any solid tumor type); HRAS overexpression (only for HNSCC tumors); KRAS and\u002For NRAS, and\u002For HRAS-mutant and\u002For amplified NSCLC or CRC; KRAS-mutant and\u002For amplified PDAC\n  * Arm #2 (Combination): Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype; non-clear cell RCC patients who are either treatment-naïve or have received any prior systemic treatment for locally advanced and metastatic RCC.\n  * Arm #3 (Combination): Patients who have received at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC.\n  * Arm #4 (Combination): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #5 (Cabozantinib monotherapy): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #6 (Cabozantinib rollover to combination): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #7 (Combination): Patients who have received at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.\n* Acceptable liver, renal, endocrine, and hematologic function.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Any use of anticancer therapy within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1.\n* Prior treatment with an FTI or HRAS inhibitor.\n* Major surgery, other than local procedures, within 28 days prior to Cycle 1 Day 1, without complete recovery.\n* Spinal cord compression, leptomeningeal disease, or clinically active CNS metastases.\n* Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent.\n* Active or prior documented autoimmune or inflammatory disorders within the past 5 years prior to Cycle 1 Day 1 (with exceptions).\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.\n* Inability to swallow, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs.\n* Inadequate cardiac and\u002For vascular function, including receipt of treatment for unstable angina, myocardial infarction, and\u002For cerebrovascular attack within the prior 6 months, mean QTcF ≥470 ms, or Class II or greater congestive heart failure.\n* Other invasive malignancy within 2 years.\n* Other protocol-defined exclusion criteria may apply.",{"count":249,"type":21},300,[251],"PHASE1","This first-in-human (FIH) dose-escalation and dose-validation\u002Fexpansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.",[254,255,256,27,257,258,259],"Solid Tumors With HRAS Alterations","Non Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Renal Cell Carcinoma (Kidney Cancer)","Non Clear Cell Renal Cell Carcinoma (nccRCC)",[139,31,138,261,262,263,264,265,266,267,32,268],"Farnesyltransferase inhibitor (FTI)","Tyrosine Kinase inhibitor (TKI)","Phase 1","KRAS G12C inhibitor","NSCLC","ccRCC","RCC","CRC","2026-06-04",{"date":271,"type":41},"2026-06-08",{"date":273,"type":41},"2023-10-18",{"date":275,"type":21},"2027-04",{"name":277,"class":48},"Kura Oncology, Inc.",38,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},"100519207","phase-1-study-of-rmc-9805-in-participants-with-kras-g12d-mutant-solid-tumors-100519207","NCT06040541","Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","Phase 1\u002F1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors","Inclusion Criteria:\n\n* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage\n* ECOG performance status 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Known or suspected leptomeningeal or active brain metastases or spinal cord compression\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\n* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)\n\nOther inclusion\u002Fexclusion criteria may apply.",{"count":287,"type":21},604,[251],"This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.",[291,256,27,292],"Non-small Cell Lung Cancer (NSCLC)","Advanced Solid Tumors",[294,265,268,32,295,296,297,298,34,299,33,35,300,301,31,302],"KRAS G12D (ON)","Non-small Cell Lung Cancer","Lung Cancer","Colorectal Cancer","Colon Cancer","Metastatic Cancer","Colorectal Neoplasms","Gastrointestinal Neoplasms","Colonic Neoplasms","2026-06-02",{"date":305,"type":41},"2026-06-03",{"date":307,"type":41},"2023-09-07",{"date":309,"type":21},"2027-04-30",{"name":150,"class":48},17,{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":239},"100637602","phase-1-study-of-lt-010391-in-participants-with-kras-g12d-mutant-solid-tumors-100637602","NCT07624214","Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors","A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-010391 Tablets in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;\n* Failed standard therapy, intolerant to standard therapy, or no standard therapy is available;\n* ECOG Performance Status of 0 or 1;\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured;\n* Primary central nervous system (CNS) tumors\n* leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion\u002Fexclusion criteria may apply.",{"count":320,"type":21},198,[251],"This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors",[291,256,27,292],"2026-05-31",{"date":305,"type":41},{"date":327,"type":21},"2026-07",{"date":329,"type":21},"2029-04",{"name":331,"class":48},"Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":239},"100637483","phase-1-dual-target-car-nk-cells-targeting-mesothelin-msln-and-muc1-in-advanced-pancreatic-ductal-adenocarcinoma-100637483","NCT07627711","Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","A Phase 1\u002F2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2\u002FMUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","DUAL-NK-PDAC","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of consent.\n* Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).\n* Unresectable locally advanced or metastatic disease with progression after at least 1 prior standard systemic therapy regimen, or intolerance\u002Fineligibility for standard therapy.\n* At least 1 measurable lesion per RECIST v1.1.\n* Tumor antigen expression by central IHC (archival or fresh biopsy): • Arm A eligibility: MSLN positive and\u002For MUC1 positive. • Arm B eligibility: CLDN18.2 positive and\u002For MUC1 positive. (Example threshold: IHC 2+ or 3+ staining in \\>=50% of tumor cells, or H-score above protocol-defined cutoff.)\n* ECOG performance status 0-1.\n* Adequate organ function (example): ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3x ULN (\\\u003C= 5x ULN with liver metastases); total bilirubin \\\u003C= 1.5x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Life expectancy \\>= 12 weeks.\n* Negative pregnancy test for individuals of childbearing potential; agreement to use effective contraception during study participation and for a protocol-defined follow-up period.\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases or carcinomatous meningitis.\n* Clinically significant uncontrolled infection (including uncontrolled bacterial, fungal, or viral infection).\n* Known active hepatitis B or hepatitis C with detectable viral load; known uncontrolled HIV infection.\n* Prior allogeneic hematopoietic stem cell transplant or solid organ transplant.\n* Prior gene-modified cellular therapy (e.g., CAR-T\u002FCAR-NK) within 6 months or prior therapy targeting the same antigen(s) Ongoing requirement for systemic immunosuppressive therapy (e.g., chronic corticosteroids above physiologic replacement).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, or NYHA class III\u002FIV heart failure) within a protocol-defined period.\n* Active autoimmune disease requiring systemic treatment in the past 2 years (replacement therapy allowed).\n* Pregnant or breastfeeding.\n* Any medical, psychiatric, or social condition that, in the investigator's opinion, would interfere with safe participation or interpretation of results.","75 Years",{"count":342,"type":21},42,[251,24],"This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and\u002For MUC1, or (B) Claudin 18.2 (CLDN18.2) and\u002For MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.",[27,346,347],"Unresectable Locally Advanced","Metastatic Disease",[349,32,350,351,352,353,354,355,356,357,358,359],"Pancreatic cancer","CAR-NK","Natural killer cells","Mesothelin","MSLN","MUC1","Claudin 18.2","CLDN18.2","Adoptive cell therapy","Immunotherapy","Biomarker-guided",{"date":269,"type":41},{"date":362,"type":41},"2026-03-02",{"date":364,"type":21},"2028-03-17",{"name":366,"class":48},"Beijing Biotech",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":388},"100619816","phase-1-study-of-rmc-5127-in-patients-with-advanced-kras-g12v-mutant-solid-tumors-100619816","NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Phase 1\u002F1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.\n* Measurable per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and\u002For inhibitors).\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":375,"type":21},574,[251],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.",[291,256,135,27,32,268,265,34,379,292],"Lung Cancer (NSCLC)",[292,34,33,32,297,268,296,295,265,36,31,141],"2026-05-28",{"date":233,"type":41},{"date":384,"type":41},"2026-01-08",{"date":386,"type":21},"2028-10",{"name":150,"class":48},5,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":412},"100610089","phase-1-a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-bms-986523-alone-and-in-combination-with-anti-cancer-agents-in-participants-with-advanced-solid-malignancies-100610089","NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","A Phase 1\u002F2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).\n* Participants must, for Arm D, have a PD-L1 expression (≥50%).\n* Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.\n\nExclusion Criteria\n\n* Participants must not have untreated central nervous system (CNS) metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted.\n* Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":397,"type":21},252,[251,24],"The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies",[401,291,256,27],"Advanced Solid Malignancies",[291,256,27,34,296,403],"Kirsten rat sarcoma viral oncogene homolog (KRAS)","2026-05-26",{"date":381,"type":41},{"date":407,"type":41},"2025-11-25",{"date":409,"type":21},"2028-10-13",{"name":411,"class":48},"Bristol-Myers Squibb",8,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":437},"100611024","phase-1-a-study-of-mr001-combined-with-chemotherapy-in-patients-with-locally-advanced-or-metastatic-pancreatic-ductal-adenocarcinoma-pdac-after-first-line-therapy-100611024","NCT07235202","A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","An Open-label, Dose-escalation and Dose-expansion Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MR001 in Combination With Standard Chemotherapy Regimens in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Who Have Progressed After First-line Therapy","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic PDAC, progressed after only one prior line of systemic therapy.\n* At least one measurable lesion per RECIST v1.1.\n* ECOG Performance Status of 0-1.\n* Life expectancy \\>3 months.\n* Adequate organ and marrow function as defined by laboratory parameters.\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Known hypersensitivity to MR001 or similar monoclonal antibodies.\n* Requirement for systemic immunosuppressive therapy within 14 days before first dosing.\n* Uncontrolled active infections or concurrent malignancies.\n* Not adequately controlled active brain metastases or leptomeningeal metastasis.\n* Clinically significant cardiovascular, renal, or hepatic disorders.\n* Pregnant or breastfeeding women.\n* Any other circumstances which the investigator considers may increase risks to subjects or interfere with the results of the trial.",{"count":421,"type":21},45,[251,24],"This Phase Ib\u002FIIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.",[27],[426,32,427,428],"MR001","CD4","TGF-β1","2026-05-21",{"date":404,"type":41},{"date":432,"type":41},"2025-12-24",{"date":434,"type":21},"2028-12-22",{"name":436,"class":48},"Shenzhen Majory Biotechnology Co., Ltd.",4,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":445,"phases":4,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":456,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":460,"locationsCount":4},"100638642","expanded-access-to-pcnat-01-for-patients-with-resected-pancreatic-ductal-adenocarcinoma-following-surgical-resection-and-adjuvant-therapy-100638642","NCT07612930","Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy","Expanded Access Program for PCNAT-01, a Personalized Tumor Neoantigen Peptide Vaccine, in Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Completion of Adjuvant Chemotherapy","Eligibility for expanded access will be determined on a case-by-case basis by the Sponsor and treating physician. Key criteria may include the following:\n\nInclusion Criteria\n\n1. Adult patients aged 18 years or older.\n2. Histologically confirmed pancreatic ductal adenocarcinoma.\n3. Prior R0 or R1 surgical resection of PDAC.\n4. Completion of standard adjuvant therapy, unless discontinued early due to intolerable toxicity as permitted after Sponsor and physician review.\n5. No evidence of disease recurrence before PCNAT-01 administration.\n6. ECOG performance status of 0 or 1, or otherwise acceptable functional status based on treating physician and Sponsor assessment.\n7. Adequate organ and marrow function to receive PCNAT-01.\n8. Availability of adequate tumor tissue for sequencing and neoantigen identification.\n9. Successful identification of sufficient patient-specific neoantigens for PCNAT-01 manufacture.\n10. Ability to provide informed consent and comply with expanded access procedures.\n11. For patients of reproductive potential, willingness to comply with pregnancy testing and contraception requirements.\n\nExclusion Criteria\n\n1. Ability to participate in the ongoing PCNAT-01 clinical trial, if trial participation is feasible and appropriate.\n2. Evidence of recurrent, metastatic, or unresectable disease before planned PCNAT-01 administration, unless specifically accepted after Sponsor and physician review.\n3. Known hypersensitivity or intolerance to PCNAT-01, Poly-ICLC, or any component of the vaccine.\n4. Active uncontrolled infection or clinically significant viral infection.\n5. Active or suspected autoimmune disease requiring systemic treatment, except protocol-permitted conditions.\n6. Immunodeficiency disease, organ transplantation requiring immunosuppression, or chronic systemic immunosuppressive therapy.\n7. Clinically significant cardiovascular disease, uncontrolled hypertension, clinically significant arrhythmia, or other uncontrolled medical condition.\n8. Recent live or live-attenuated vaccination, recent prohibited anticancer therapy, or recent major surgery within a timeframe considered unsafe by the treating physician and Sponsor.\n9. Unresolved clinically significant toxicity from prior anticancer therapy.\n10. Pregnancy or breastfeeding.\n11. Any condition that, in the opinion of the treating physician or Sponsor, would make expanded access treatment unsafe, interfere with patient monitoring, or compromise the ongoing clinical development program.","EXPANDED_ACCESS","This expanded access program provides a potential pathway for eligible patients with resected pancreatic ductal adenocarcinoma (PDAC) to receive PCNAT-01, an investigational, personalized tumor neoantigen peptide vaccine, outside of the ongoing clinical trial when participation in the clinical trial is not possible or feasible. PCNAT-01 is intended for use in disease-free patients following surgical resection and completion of standard adjuvant therapy to reduce the risk of recurrence. Access is subject to Sponsor review, regulatory authorization, institutional review board approval, physician oversight, successful patient-specific vaccine manufacture, and confirmation that treatment under expanded access will not interfere with the ongoing clinical development program.",[27],[33,32,449,450,451,452,453,454,455],"Personalized Neoantigen Vaccine","Peptide Vaccine","Tumor Neoantigen","Cancer Vaccine","Recurrence Prevention","Recurrence-Free Survival","Adjuvant Therapy","AVAILABLE","2026-05-19",{"date":459,"type":41},"2026-05-29",{"name":461,"class":48},"Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":469,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100639609","phase-1-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-xh001-injection-as-adjuvant-therapy-in-patients-with-high-risk-recurrent-solid-tumors-100639609","NCT07594964","To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors","Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors After Radical Surgery","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form;\n* Aged between 18 and 70 years old, male or female;\n* Patients with high-risk recurrent solid tumors confirmed by pathology after radical surgery mainly include pancreatic ductal adenocarcinoma, biliary tract malignancies, hepatocellular carcinoma, gastric adenocarcinoma, etc.\n* Expected survival duration ≥12 months;\n* ECOG score of 0-1;\n* White blood cell count≥ 3.0×10\\^9\u002FL; Neutrophil count ≥ 1.0×10\\^9\u002FL; Platelet count ≥75×10\\^9\u002FL; Hemoglobin (Hb)≥ 90g\u002FL; Creatinine clearance rate≥50mL\u002Fmin \\[calculated using the Cockcroft-Gault formula\\]; Alanine aminotransferase ≤ 3×ULN (patients with hepatocellular carcinoma or biliary tract malignancy \\\u003C5×ULN); Aspartate aminotransferase ≤ 3×ULN ((patients with hepatocellular carcinoma or biliary tract malignancy \\\u003C5×ULN); Total bilirubin ≤ 3×ULN; Serum albumin \\> 28g\u002FL; Coagulation: Prothrombin time prolongation ≤ 4s;\n\nExclusion Criteria:\n\n* There is evidence of tumor residue, recurrence or metastasis during screening;\n* Has a history of hepatic encephalopathy or liver transplantation;\n* Has clinical uncontrolled (requiring repeated drainage) pericardial effusion, pleural effusion and moderate or severe ascites;\n* Requires long-term systemic administration of antiallergic drugs, or has severe hypersensitivity reactions (\\>=Grade 3) to XH001 injection and\u002For any of its excipients;\n* New cerebrovascular accidents within 6 months before screening (including ischemic stroke, hemorrhagic stroke and transient ischemic attack)；\n* Individuals who have experienced acute myocardial infarction, or have uncontrolled angina pectoris, uncontrolled arrhythmia, severe heart failure (NYHA heart failure classification standard\\>= Grade III) and other cardiovascular diseases within 6 months before screening;\n* Patients with pancreatic ductal adenocarcinoma (PDAC) have the following conditions: 1) Borderline resectable pancreatic ductal adenocarcinoma; 2) Tumor tissue containing neuroendocrine tumor components (i.e., mixed type); 3) Pancreatic tumor types other than PDAC; 4) Persistent severe diarrhea after surgery;\n* Patients with biliary tract malignancy have the following conditions: 1) Pancreatic or ampullary cancer; 2) Unresolved biliary obstruction; 3) Insufficient surgical biliary drainage, and there are signs of infection;\n* .Subjects with hepatocellular carcinoma exhibit the following conditions: 1) The tumor contains components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and biliary tract malignancy; 2) Received more than one cycle of adjuvant TACE after surgery or ablation;\n* Patients with gastric adenocarcinoma have the following conditions: severe postoperative complications (severe postoperative infection, anastomotic leakage and gastrointestinal bleeding);\n* Have active or poorly controlled severe infections;\n* .Patients with other malignancies within 5 years before enrollment, except for those with a history of appropriately treated and cured cervical carcinoma in situ, breast carcinoma in situ, or skin basal cell carcinoma;\n* Any history of autoimmune diseases (regardless of whether they are currently active),；\n* Who have previously received similar therapeutic tumor vaccines;","70 Years",{"count":471,"type":21},48,[251],"The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with high-risk recurrent solid tumors after radical surgery.\n\nThe main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does XH001 injection combined with standard adjuvant treatment induce a specific T-cell response, and can it prolong the patient's relapse-free survival?",[475,27,476,477],"Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)",[479,480],"mRNA","Neoantigen specific tumor vaccine","2026-05-18",{"date":457,"type":41},{"date":484,"type":41},"2025-08-25",{"date":486,"type":21},"2030-06-30",{"name":488,"class":48},"Shenzhen Xinhe Biomedical",2,{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":239},"100639866","phase-1-nalirifoxadebrelimabpulsar-for-advanced-pancreatic-cancer-100639866","NCT07595172","NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","A Phase I\u002FII Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Age: 18-75 years, regardless of gender.\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).\n* Previously untreated, locally advanced unresectable or metastatic PDAC, with at least one measurable lesion (RECIST v1.1) not previously irradiated.\n* ECOG Performance Status (PS): 0-1.\n* Expected survival ≥ 3 months.\n* Willing and able to comply with study procedures, treatment, and follow-up.\n* No contraindications to radiotherapy.\n* Adequate organ function: WBC ≥ 2.5×10⁹\u002FL, ANC ≥ 1.5×10⁹\u002FL; Platelets ≥ 75×10⁹\u002FL; Hemoglobin (HGB) ≥ 90 g\u002FL (no transfusion or EPO dependence within 7 days); Total bilirubin (Tbil) ≤ 1.5×ULN; ALT\u002FAST ≤ 5×ULN;Albumin ≥ 30 g\u002FL; INR ≤ 1.5×ULN; Serum creatinine (Cr) ≤ 1.5×ULN Urine protein ≤ 1+\n* HBsAg-positive patients must have HBV-DNA ≤ 1×10³ IU\u002FmL (copies\u002FmL). If HBV-DNA ≥ 1×10³ IU\u002FmL, patients may still be eligible if chronic HBV is stable and not expected to increase risk, per investigator assessment.\n* Voluntary participation with signed informed consent form.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity to chimeric, human(ized) antibodies, or fusion proteins.\n* Pregnant or breastfeeding women, or men\u002Fwomen of childbearing potential unwilling\u002Funable to use effective contraception during the study.\n* Other malignancies within 5 years, except: Malignancies treated with curative intent and no known active disease for ≥5 years with low recurrence risk; Adequately treated non-melanoma skin cancer or lentigo maligna without disease evidence; Adequately treated carcinoma in situ (e.g., cervical, breast) with no current disease.\n* Symptomatic moderate\u002Fsevere pleural effusion or ascites.\n* Active bleeding or coagulopathy (PT \\>16s, APTT \\>43s, INR \\>1.5×ULN), bleeding tendency, or current use of thrombolytics\u002Fanticoagulants\u002Fantiplatelets.\n* GI bleeding within 6 months or high bleeding risk (e.g., active ulcer with occult blood++). If occult blood+ persists, endoscopy required.\n* High-risk esophageal\u002Fgastric varices needing intervention.\n* History of drug abuse, psychiatric disorder, or inability to abstain.\n* Solid organ\u002Fbone marrow transplant, or active autoimmune disease requiring systemic treatment within 2 years.\n* Immunodeficiency or HIV infection.\n* Objective evidence of pulmonary fibrosis, interstitial lung disease, pneumoconiosis, radiation-\u002Fdrug-induced pneumonitis, or severely impaired pulmonary function.\n* Major surgery within 4 weeks or minor surgery within 1 week (e.g., tooth extraction).\n* Vaccination within 30 days before the first dose.\n* Abdominal fistula, GI perforation, or abscess within 4 weeks.\n* Any clinically significant abnormality affecting safety per investigator, including: Active infection requiring systemic therapy; Uncontrolled diabetes\u002Fhypertension (BP \\>140\u002F90 mmHg despite ≤2 antihypertensives); Myocardial infarction within 6 months; Thyroid dysfunction (\\>NCI CTCAE v4.0 Grade 1).\n* Other conditions deemed ineligible by the investigator.",{"count":498,"type":21},55,[251,24],"This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.",[27,502],"Locally Advanced and Metastatic Pancreatic Cancer",[504,505,506,32],"chemotherapy","immunotherapy","radiotherapy","2026-05-16",{"date":457,"type":41},{"date":510,"type":21},"2026-04",{"date":148,"type":21},{"name":513,"class":238},"West China Hospital",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100640724","panuri-performance-study-100640724","NCT07587866","Panuri Performance Study","Evaluation of the Performance of Panuri - Test for Detection of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Arm 1 (Target Arm):\n\n  * Adults 18 years and older\n  * Presenting with symptoms supporting a clinical suspicion for pancreatic cancer by the healthcare provider, including but not limited to jaundice, abdominal or back pain, fatty stools, unexplained weight loss, loss of appetite, chronic fatigue, nausea, vomiting, indigestion, bloating, gas, diarrhea, constipation, itching, dark urine, fever, and swelling of the legs.\n* Arm 2 (Enriched Arm):\n\n  * Adults 18 years and older\n  * Scheduled for a procedure involving pancreatic histopathological assessment due to suspicion of pancreatic cancer.\n\nExclusion Criteria:\n\n* For subjects in the enriched arm, imaging results are highly suspicious for non-PDAC pancreatic cancer.\n* Patients enrolled in a pancreatic cancer screening program.\n* Prior diagnosis of pancreas malignancy, including pathological diagnoses and suspicion of pancreatic cancer based on clinical, histopathological or radiological results. Exceptions include: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMN), mucinous cystadenoma of the pancreas (MCN), serous cystadenomas (SCN) or other benign pancreatic lesions and cystic lesions without features suggestive of malignancy.\n* History of pancreatic resection\n* Presenting with concurrent symptoms or suspicion of urinary tract infection Diagnosis of any urinary tract infection within the last 30 days, except for cases that have been resolved with antibiotics discontinued at least 14 days prior to enrollment\n* Diagnosed with stage 3b to 5 chronic kidney diseases (CDK3b-CDK5), acute kidney disease in last 3 months, nephrotic syndrome in the last 6 months, or other kidney diseases associated with proteinuria\n* Diagnosed with any conditions that increase bilirubin levels within the last 6 months\n* Self-reported or documented elevated blood bilirubin levels within the past 3 months, defined as exceeding 1.5 times the upper limit of normal specific to the test laboratory\n* Diagnosis of any cancer within the past 5 years\n* Chemotherapy or anti-neoplastic therapy within the last 5 years\n* Any medical or psychological conditions that preclude compliance with study procedures.\n* Patients without any clinical signs or symptoms of pancreatic cancer\n* Inability to provide written informed consent.\n* Pregnant or breastfeeding women\n* Current participation in another drug or device study or planned participation prior to completion of sample collection procedures (i.e., approximately 1.5 months)",{"count":522,"type":21},1100,"The main purpose of the study is to assess the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma (PDAC) the most common type of pancreatic cancer that accounts for approximately 90% of all pancreatic cancer cases.\n\nThe study aims to characterize the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma in patients with symptoms supporting a clinical suspicion of pancreatic cancer The Panuri test is intended for professional laboratory use for diagnostic purposes.",[27],[526,527],"in vitro diagnostic assay","clinical performance study","2026-05-12",{"date":530,"type":41},"2026-05-14",{"date":532,"type":21},"2026-05",{"date":534,"type":21},"2028-01",{"name":536,"class":48},"Urteste S.A",28,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100468454","phase-1-study-of-rmc-6236-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras-100468454","NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","Inclusion Criteria:\n\n* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization\u002Fexpansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).\n* Treatment naive or have received prior standard therapy appropriate for tumor type and stage\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Active, untreated brain metastases\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\n* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and\u002For impact their ability to comply with the protocol prior\u002Fconcomitant therapy\n\nOther inclusion\u002Fexclusion criteria may apply.",{"count":546,"type":21},754,[251,24],"Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.",[291,256,27,292],[31,295,296,297,298,299,34,33,265,268,32,35,551,300,302,552,301,553,554,555,556,557,558,559,36],"Carcinoma, Pancreatic Ductal","Intestinal Neoplasms","Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Neoplastic Processes","Thoracic Neoplasms","Antineoplastic Agents","Melanoma","Gynecological Cancers",{"date":561,"type":41},"2026-05-15",{"date":563,"type":41},"2022-05-31",{"date":565,"type":21},"2027-07-26",{"name":150,"class":48},21,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":22,"phases":577,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":489},"100635582","nutrition-intervention-for-pancreatic-cancer-100635582","NCT07554560","Nutrition Intervention for Pancreatic Cancer","Feasibility, Tolerance, and Fat Metabolism Pilot Study of a Structured Lipid Medical Food in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor diagnosis and age greater than or equal to 18 years\n* Life expectancy of 4 months or greater\n* Oral or enteral tube feeding for \\> 60% daily calories\n* For patients with NET, evidence of GI dysfunction such as \\>5% unintentional weight loss, increased number of bowel movements¸change in stool consistency (e.g., soft stool or diarrhea), as documented in the medical record and confirmed by the treating oncologist.\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Unable to consume food by mouth (oral intake)\n* Allergy to soy lecithin product ingredients\n* Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team\n* Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors\n* Patients with diminished capacity to consent",{"count":576,"type":21},18,[578],"NA","Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.",[27,581],"Pancreatic Neuroendocrine Tumor (NET)",[33,583,584,585,586,587],"Pancreatic Neuroendocrine Tumor","Exocrine pancreatic insufficiency","Fat malabsorption","Quality of life","Gastrointestinal symptoms","2026-05-01",{"date":590,"type":41},"2026-05-07",{"date":592,"type":41},"2026-04-07",{"date":594,"type":21},"2027-06",{"name":596,"class":238},"Children's Hospital of Philadelphia",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":605,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":4},"100636113","phase-2-sacituzumab-tirumotecan-for-pancreatic-cancer-100636113","NCT07561463","Sacituzumab Tirumotecan for Pancreatic Cancer","A Phase II Trial of Sacituzumab Tirumotecan for Previously Treated Locally Advanced or Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n1. Voluntary participation with written informed consent provided\n2. Age ≥18 years at the time of signing the informed consent form\n3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)\n4. Failure of or disease progression after at least one prior line of systemic therapy for locally advanced or metastatic pancreatic cancer\n5. At least one measurable target lesion at baseline per RECIST 1.1 criteria (a single measurable lesion must not have received prior radiotherapy, or must have demonstrated clear progression after radiotherapy)\n6. ECOG performance status score of 0-2\n7. Adequate organ and bone marrow function (including hematologic, hepatic, renal, and coagulation parameters meeting specified criteria)\n8. Subjects of childbearing potential must use highly effective contraception, and female subjects must have a negative pregnancy test\n9. Ability and willingness to comply with study-related procedures.\n\nExclusion Criteria:\n\n1. History of or current presence of central nervous system metastases\n2. Presence of untreated or unstable spinal cord compression\n3. High risk of gastrointestinal or intra-abdominal bleeding\n4. Prior treatment with TROP2-targeted agents or antibody-drug conjugates (ADCs)\n5. Requirement for strong CYP3A4 inhibitors or inducers within 2 weeks prior to the first dose, or inability to avoid their use during the study\n6. History of severe dry eye syndrome, meibomian gland disease, or other corneal disorders that may impair corneal healing\n7. Major surgery within 28 days prior to the first dose (excluding palliative procedures), or receipt of curative radiotherapy within 3 months\n8. Presence of other malignancies within 3 years prior to the first treatment (except for certain definitively treated cancers)\n9. Uncontrolled severe systemic diseases such as cardiovascular or cerebrovascular disease, diabetes mellitus, or hypertension\n10. History of interstitial lung disease or non-infectious pneumonitis, or current related lesions\n11. Presence of severe underlying pulmonary disease, autoimmune disease, or prior total pneumonectomy\n12. Active chronic inflammatory bowel disease, gastrointestinal obstruction, or other severe gastrointestinal disorders\n13. Tumor invasion of critical organs or vessels with associated symptoms, or risk of fistula formation\n14. Toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (except for low-risk toxicities)\n15. Active hepatitis B, hepatitis C, HIV infection, or active syphilis\n16. Known allergy to the investigational drug or its components, or history of severe hypersensitivity to other biologic agents\n17. Severe infection within 4 weeks prior to dosing, or active infection requiring systemic therapy within 2 weeks\n18. Receipt of non-specific immunomodulatory therapy or antitumor traditional Chinese medicine within 2 weeks prior to dosing\n19. Receipt of live vaccines within 30 days prior to dosing or planned during the study period\n20. Pregnant or breastfeeding women, or individuals of childbearing potential who are not using highly effective contraception as required\n21. Individuals considered vulnerable populations (e.g., patients with psychiatric disorders or critically ill patients), or any other condition deemed unsuitable for enrollment by the investigator.",{"count":215,"type":21},[24],"This is a multicenter, prospective, open-label Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab govitecan monotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma who have failed at least one prior line of therapy, and to explore the potential correlation between baseline tumor tissue TROP-2 expression and treatment efficacy. The study plans to enroll 30 eligible subjects, who will receive sacituzumab govitecan at 5 mg\u002Fkg via intravenous infusion every 2 weeks as one treatment cycle, until disease progression or intolerable toxicity occurs. The primary endpoint is Objective Response Rate (ORR); secondary endpoints include Progression-Free Survival (PFS), Overall Survival (OS), Disease Control Rate (DCR), Duration of Response (DOR), and the incidence and severity of Treatment-Related Adverse Events (TRAEs).",[27],"2026-04-28",{"date":588,"type":41},{"date":611,"type":21},"2026-04-01",{"date":613,"type":21},"2027-07-01",{"name":615,"class":238},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":642},"100612578","phase-2-a-clinical-trial-testing-the-safety-of-bnt327-an-investigational-drug-and-how-well-it-works-when-combined-with-chemotherapy-for-people-who-have-not-been-treated-yet-for-pancreatic-cancer-100612578","NCT07255404","A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","A Phase II, Multi-site, Randomized, Open-label, Trial of BNT327 in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Have a histologically or cytologically confirmed metastatic PDAC. A tissue sample, archival or fresh, must be provided during the screening period. In case it is not feasible to meet the required tumor tissue criteria, approval by the sponsor's medical monitor is needed for enrollment.\n* Have not received prior systemic therapy for unresectable metastatic PDAC. For participants who have received prior induction chemotherapy, concurrent chemoradiotherapy, or adjuvant\u002Fneoadjuvant chemotherapy for curative-intent, the interval should be at least 6 months from the end of the last treatment to relapse.\n* Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures) are not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system \\[CNS\\] metastasis should not be considered as a measurable lesion).\n* Agree to discontinue strong inhibitors or inducers of cytochrome P450 enzyme (CYP3A), CYP2C8, glucuronosyltransferase 1 family, polypeptide A cluster 1A (UGT1A1) at least 2 weeks prior to starting study treatment, and change to other treatment regimens at screening if such drugs are used.\n\nExclusion Criteria:\n\n* Have received any of the following therapies or drugs before study enrollment:\n\n  * Have received prior systemic anticancer therapy for unresectable metastasis disease.\n  * Any anticancer therapy, including systemic, palliative, biologic, immunostimulatory, or immunosuppressive treatment within 4 weeks (or five half-lives, whichever is longer) before starting study treatment.\n  * PD(L)-1\u002FVEGF bispecific antibody, including monotherapy with either category or combinations thereof.\n  * Systemic corticosteroids (at a dosage greater than 10 mg\u002Fday of prednisone or an equivalent dose of other corticosteroids) within 14 days before starting study treatment. Exception: Excluding local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergies) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens).\n  * Vaccinations with live attenuated vaccine(s) within 4 weeks before starting study treatment.\n  * Broad-spectrum intravenous antibiotics therapy within 2 weeks before starting study treatment.\n  * Any non-study investigational medicinal product within five half-lives of the first dose or within 4 weeks, whichever is longer, before initiation of study treatment in this study or ongoing participation in the active treatment phase of another interventional clinical study.\n  * Antiplatelet drugs, such as aspirin (\\>325 mg\u002Fday), clopidogrel (\\>75 mg\u002Fday), dipyridamole, ticlopidine or cilostazol, etc., within 10 days before starting study treatment to avoid inclusion of participants who have used platelet aggregation inhibitors before the study.\n* Have undergone major organ surgery (core needle biopsies are allowed \\>7 days before starting study treatment), open biopsy, significant trauma, or invasive dental procedures (such as dental implants) within 28 days before starting study treatment, or a planned\u002Fanticipated need for major surgery during the study treatment period. Placement of vascular infusion devices is allowed. Note: If participant has had major surgery, they must have recovered adequately from the toxicity and\u002For complications from the treatment before starting study treatment.\n* Have received allogeneic hematopoietic stem cell transplantation or organ transplantation.\n* Have spinal cord compression or CNS metastases that are untreated and symptomatic or require treatment with corticosteroids or anticonvulsants for associated-symptom control. Exception: Treated brain metastases which are no longer symptomatic and for which no corticosteroid or anticonvulsant treatment is needed (the participant must have recovered from the acute toxic effect of radiotherapy).\n* Have active autoimmune disease or history of autoimmune diseases with anticipated relapse (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for those with clinically stable autoimmune thyroid disease or type 1 diabetes mellitus.\n* Have had other malignant tumors within 5 years before starting study treatment. Exception: Those who have been cured with local treatment (such as basal cell or squamous-cell carcinoma of the skin, superficial or noninvasive bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, and papillary carcinoma of thyroid and early-stage prostate cancer).\n* Have heart conditions as specified in the protocol within 6 months before starting study treatment.\n* Have uncontrolled hypertension or poorly controlled diabetic conditions as specified in the protocol before starting study treatment.\n* History of myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months before starting study treatment.\n* History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 3 months prior to randomization, unless the participant has been fully treated (e.g., inferior vena cava filter placed) and\u002For adequately anticoagulated on a prophylactic dose.\n* Have serious or non-healing wounds, ulcers, or (incompletely healed) bone fractures. This includes history (within 6 months before starting the study treatment) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices, or acute gastrointestinal bleeding. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation\u002Ffistula and\u002For the underlying process causing the fistula\u002Fperforation.\n* Have significant risk of hemorrhage (in the opinion of the investigator) or evidence of major coagulation disorders as specified in the protocol.\n* Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Those with indwelling catheters (e.g., PleurX) are allowed.\n* Participants with a history of serious Grade 3 or higher immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy. Participants with a history of Grade 3 or higher irAEs that did not lead to treatment discontinuation of a prior immunotherapy may be enrolled at the investigator's discretion.\n* Have adverse events (AEs) from prior antitumor therapy that have not returned to Grade 1 (graded by CTCAE v5.0 criteria) or below (unless the investigator determines that certain AEs pose no safety risk to participants, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).\n* Have gastrointestinal symptoms or conditions as specified in the protocol.\n* History of serious allergic diseases, history of serious allergy to drugs (including unlisted investigational drug) or known allergy or intolerance to any ingredient of the study treatment.\n* Have superior vena cava syndrome or symptoms of spinal cord compression.\n* Have active, or a history of, pneumonitis requiring treatment with steroids, or have active or a history of interstitial lung disease. Those with a history of pulmonary fibrosis or with currently diagnosed severe lung diseases such as interstitial pneumonia, pneumoconiosis, chemical pneumonitis, or any other condition resulting in significant impairment in lung function. Exception: Asymptomatic interstitial changes caused by previous radiotherapy, chemotherapy, or other factors such as smoking are allowed.\n* Have a known history of tuberculosis that was not successfully treated.\n* Have active syphilis. Participants with inactive previous infection could be eligible: Infection with a positive non-specific antibody test for syphilis (e.g., TRUST \\[Toluidine Red Unheated Serum Test\\], Rapid Plasma Reagin \\[RPR\\], TP-PA \\[Treponema pallidum Particle Agglutination\\]) or have a positive syphilis-specific antibody test (e.g., TPPA) (a positive \"syphilis-specific antibody test\" but a negative \"non-specific antibody test for syphilis\" for more than 1 year) infection.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria apply.",{"count":624,"type":21},105,[24],"This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (BNT327) in combination with chemotherapy.",[27],[32,629,630,358,631,632,633],"Bispecific antibody","Metastatic pancreatic cancer","Immunotherapy in combination with chemotherapy","Programmed death-ligand 1 (PD-L1)","Vascular endothelial growth factor(-A) (VEGF-A)",{"date":635,"type":41},"2026-04-29",{"date":637,"type":41},"2025-12-04",{"date":639,"type":21},"2028-08",{"name":641,"class":48},"BioNTech SE",10,{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":665,"leadSponsor":667,"locationsCount":239},"100634619","artidis-nanomechanical-signature-profiling-of-pancreatic-cancer-specimens-100634619","NCT07542041","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)","ANoPs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and willingness to sign a written informed consent form\n* Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study",{"count":101,"type":21},[578],"The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.\n\nThe main questions this study aims to answer are:\n\n* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?\n* How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?\n\nThis is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.\n\nParticipants will:\n\n* Undergo a standard-of-care pancreatic biopsy or surgical procedure\n* Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device\n* Continue to receive standard treatment and care, which is not influenced by the study\n* Have clinical data, imaging results, and treatment outcomes collected\n* Be followed every 3 months for up to 2 years\n\nThe study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.",[34,35,27,655],"Pancreatic Lesions Located at the Body or the Tail",[657,658,659,660,33,34],"Atomic Force Microscopy","Neoadjuvant Therapy","Nanomechanical Profiling","NEO-Match","2026-04-14",{"date":663,"type":41},"2026-04-21",{"date":510,"type":21},{"date":666,"type":21},"2030-05",{"name":668,"class":48},"ARTIDIS AG",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":676,"targetDuration":678,"studyType":216,"phases":4,"briefSummary":679,"conditions":680,"keywords":681,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":687,"lastUpdatePostDateStruct":688,"startDateStruct":690,"completionDateStruct":691,"leadSponsor":693,"locationsCount":239},"100595786","metabolomic-and-immune-microbiome-profiling-for-unresectable-pancreatic-cancer-100595786","NCT07036978","Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer","Integrative Metabolomic and Immune-Microbiome Profiling for Personalised Treatment Stratification in Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Unresectable disease status determined by a multidisciplinary tumour board (either locally advanced disease encasing critical vessels or distant metastases present).\n2. Planned initiation of systemic therapy (first-line chemotherapy or chemo + experimental immunotherapy trial) as part of standard care - this ensures a uniform starting point for outcome measurement.\n3. Adequate organ function to undergo therapy (renal, hepatic, bone marrow parameters within acceptable range) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating patients well enough to participate and undergo required blood draws and sample collection.\n4. Ability to provide informed consent, with no severe comorbid conditions that would preclude study procedures (e.g. unable to provide stool sample or undergo blood draws).\n\nExclusion Criteria:\n\n1. Prior systemic therapy for metastatic PDAC.\n2. Current use of long-term antibiotics or probiotics that could significantly alter the gut microbiome unless they are willing to pause these interventions (to avoid confounding in microbiome analysis).\n3. Co-existing active malignancy that could confound metabolomic or immune readouts, unless it is a low-grade, early cancer in remission.",{"count":677,"type":21},140,"2 Years","Brief Summary\n\nThe goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are:\n\n* What serum metabolomic profiles predict treatment response and patient survival?\n* How do immune response markers and gut microbiome composition correlate with therapeutic outcomes?\n* Can a combined multi-omic stratification algorithm enhance personalised therapy planning?\n\nParticipants, who have been diagnosed with unresectable locally advanced or metastatic PDAC and are undergoing systemic therapy and chemoradiotherapy, will:\n\n* Provide serum samples for comprehensive metabolomic profiling via high-performance liquid chromatography-mass spectrometry.\n* Undergo immune profiling through flow cytometry.\n* Provide stool samples for gut microbiome analysis using 16S rRNA sequencing.\n* Be followed longitudinally to correlate these multi-omic findings with clinical outcomes.\n\nResearchers anticipate that integrating these multi-omic analyses will facilitate personalised therapy approaches, potentially improving patient outcomes.",[27],[682,683,684,685,686],"Pancreatic ductal adenocarcinoma","Metabolomics","Microbiome","Immune profiling","Multi-omic integration","2026-04-13",{"date":689,"type":41},"2026-04-15",{"date":588,"type":21},{"date":692,"type":21},"2033-07-31",{"name":237,"class":238}]